MX2019010338A - Administracion concomitante de moduladores de receptores de glucocorticoides e inhibidores de cyp3a. - Google Patents

Administracion concomitante de moduladores de receptores de glucocorticoides e inhibidores de cyp3a.

Info

Publication number
MX2019010338A
MX2019010338A MX2019010338A MX2019010338A MX2019010338A MX 2019010338 A MX2019010338 A MX 2019010338A MX 2019010338 A MX2019010338 A MX 2019010338A MX 2019010338 A MX2019010338 A MX 2019010338A MX 2019010338 A MX2019010338 A MX 2019010338A
Authority
MX
Mexico
Prior art keywords
inhibitors
grm
concomitant administration
itraconazole
ketoconazole
Prior art date
Application number
MX2019010338A
Other languages
English (en)
Inventor
K Belanoff Joseph
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59958459&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019010338(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of MX2019010338A publication Critical patent/MX2019010338A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

El solicitante proporciona métodos para tratar enfermedades que incluyen el síndrome de Cushing y los cánceres sensibles a las hormonas mediante la administración concomitante de un modulador del receptor de glucocorticoides (GRM) y los inhibidores de esteroidogénesis, y mediante la administración concomitante de un inhibidor de GRM y CYP3A. El GRM puede ser, por ejemplo, mifepristona; los inhibidores de CYP3A o los inhibidores de esteroidogénesis (colectivamente ''inhibidores'') pueden ser, por ejemplo, ketoconazol o itraconazol. Los inhibidores pueden causar toxicidad u otras reacciones adversas graves; la administración concomitante de inhibidores con otros fármacos puede aumentar el riesgo de dicha toxicidad y reacciones adversas debido a los inhibidores y/u otros fármacos. El solicitante ha encontrado sorprendentemente que los GRM pueden administrarse a sujetos que reciben inhibidores sin aumentar el riesgo de reacciones adversas; por ejemplo, el solicitante ha descubierto que la mifepristona se puede administrar concomitantemente con ketoconazol o itraconazol, proporcionando una administración concomitante segura de GRM y ketoconazol o itraconazol. En modalidades, la dosis de GRM puede reducirse durante la administración concomitante de GRM con inhibidores.
MX2019010338A 2017-03-01 2018-02-28 Administracion concomitante de moduladores de receptores de glucocorticoides e inhibidores de cyp3a. MX2019010338A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762465772P 2017-03-01 2017-03-01
US201762466867P 2017-03-03 2017-03-03
PCT/US2018/020336 WO2018160775A1 (en) 2017-03-01 2018-02-28 Concomitant administration of glucocorticoid receptor modulators and cyp3a inhibitors

Publications (1)

Publication Number Publication Date
MX2019010338A true MX2019010338A (es) 2019-10-14

Family

ID=59958459

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010338A MX2019010338A (es) 2017-03-01 2018-02-28 Administracion concomitante de moduladores de receptores de glucocorticoides e inhibidores de cyp3a.

Country Status (11)

Country Link
US (6) US20170281651A1 (es)
EP (1) EP3589288A4 (es)
JP (2) JP7218294B2 (es)
KR (1) KR102532583B1 (es)
CN (1) CN110352058A (es)
AU (1) AU2018229355B2 (es)
CA (1) CA3052668A1 (es)
IL (1) IL269009B2 (es)
MX (1) MX2019010338A (es)
SG (1) SG11201907854VA (es)
WO (1) WO2018160775A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170281651A1 (en) 2017-03-01 2017-10-05 Corcept Therapeutics, Inc. Concomitant administration of glucocorticoid receptor modulators and cyp3a or steroidogenesis inhibitors
US11285145B2 (en) 2020-05-27 2022-03-29 Corcept Therapeutics Incorporated Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4
AU2021279006A1 (en) * 2020-05-27 2022-12-15 Corcept Therapeutics Incorporated Concomitant administration of glucocorticoid receptor modulator relacorilant and CYP2C9 substrates
US20230372312A1 (en) * 2022-05-20 2023-11-23 Corcept Therapeutics Incorporated Methods of Treating Cushing's syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020016293A1 (en) 2000-04-21 2002-02-07 Ratain Mark J. Flavopiridol drug combinations and methods with reduced side effects
US7163934B2 (en) 2001-05-04 2007-01-16 Corcept Therapeutics, Inc. Methods for treating delirium glucocorticoid receptor-specific antagonists
US20070254025A1 (en) 2006-04-27 2007-11-01 Cronk Peter J Oral contraceptive and acne medication combination and treatment of acne with reduced side effects
EP1886695A1 (en) 2006-06-27 2008-02-13 Speedel Experimenta AG Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist
MX2009004385A (es) 2006-10-23 2009-05-22 Merck & Co Inc Derivados de 2-[1-fenil-5-hidroxi-4alfa-metil-hexahidrociclopenta [f]indazol-5-il]etil fenilo como ligandos del receptor glucocorticoide.
US8598149B2 (en) 2007-08-30 2013-12-03 Corcept Therapeutics, Inc. Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders treatable with glucocorticoid receptor antagonists
ES2626131T3 (es) 2007-10-17 2017-07-24 Laboratoire Hra Pharma Antagonistas del receptor de glucocorticoides tales como mifepristona para tratar el síndrome de Cushing
US8216495B2 (en) * 2008-03-25 2012-07-10 Formac Pharmaceuticals N.V. Preparation method for solid dispersions
US9216221B2 (en) 2008-11-07 2015-12-22 University Of Sheffield Medicament and method of diagnosis for treating subclinical Cushing's syndrome
US20100135956A1 (en) 2008-11-21 2010-06-03 Auspex Pharmaceuticals, Inc. Steroid modulators of progesterone receptor and/or glucocorticoid receptor
CA2999345A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating cancer and non-neoplastic conditions
PE20121429A1 (es) * 2009-10-29 2012-11-06 Aventis Pharma Sa Nuevo uso antitumoral de cabazitaxel
EP3233916A4 (en) * 2014-12-19 2018-06-06 Alder Biopharmaceuticals, Inc. Humanized anti-acth antibodies and use thereof
US9943526B2 (en) 2015-04-21 2018-04-17 Corcept Therapeutics, Inc. Optimizing mifepristone levels for cushing's patients
IL309712A (en) 2015-05-18 2024-02-01 Corcept Therapeutics Inc Methods for diagnosing and determining treatment for Cushing's syndrome
US20170281651A1 (en) 2017-03-01 2017-10-05 Corcept Therapeutics, Inc. Concomitant administration of glucocorticoid receptor modulators and cyp3a or steroidogenesis inhibitors

Also Published As

Publication number Publication date
AU2018229355B2 (en) 2024-02-15
CN110352058A (zh) 2019-10-18
SG11201907854VA (en) 2019-09-27
US20190117676A1 (en) 2019-04-25
AU2018229355A1 (en) 2019-08-15
EP3589288A1 (en) 2020-01-08
US20200147107A1 (en) 2020-05-14
KR102532583B1 (ko) 2023-05-12
IL269009B2 (en) 2024-02-01
US20170326157A1 (en) 2017-11-16
KR20190122239A (ko) 2019-10-29
IL269009B1 (en) 2023-10-01
US10195214B2 (en) 2019-02-05
US20230414635A1 (en) 2023-12-28
CA3052668A1 (en) 2018-09-07
US10842800B2 (en) 2020-11-24
JP2020509032A (ja) 2020-03-26
JP7218294B2 (ja) 2023-02-06
US20220088036A1 (en) 2022-03-24
JP2023052618A (ja) 2023-04-11
EP3589288A4 (en) 2020-12-30
US20170281651A1 (en) 2017-10-05
IL269009A (en) 2019-10-31
US11969435B2 (en) 2024-04-30
WO2018160775A1 (en) 2018-09-07

Similar Documents

Publication Publication Date Title
MX2019010338A (es) Administracion concomitante de moduladores de receptores de glucocorticoides e inhibidores de cyp3a.
ECSP22023220A (es) Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue
MX2017007321A (es) Terapias de combinacion.
EA201892657A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
PH12019500208A1 (en) Spiro-lactam nmda receptor modulators and methods of using same
PH12017501097A1 (en) Sunitinib formulations and methods for use thereof in treatment of ocular disorders
PH12019500202A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500206A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500207A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
CR20190433A (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
MX2019001322A (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos.
MX2019003173A (es) Terapia de combinacion con agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada.
PH12018502738A1 (en) Compositions, devices, and methods for the treatment of alcohol use disorder
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
CR20220355A (es) Compuestos activos frente a receptores nucleares
MX2021005992A (es) Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión.
MX2022007265A (es) Compuestos activos frente a receptores nucleares.
PH12020551179A1 (en) Methods for treating mitochondrial disorder
MX2017005163A (es) Composiciones de liberación prolongada de onapristona y métodos.
MX2018000257A (es) Dispositivo de suministro de un solo uso que tiene caracteristicas de seguridad.
MX2016014740A (es) Un metodo para el tratamiento de trastornos del movimiento con befiradol.
MX2021007522A (es) Composiciones, dispositivos y metodos para el tratamiento de trastornos por sobredosis y basados en recompensas.
MX2018005876A (es) Regimen de dosificacion de plasminogeno para la cicatrizacion de heridas.
MX2022007516A (es) Metodos para tratar el cancer utilizando una combinacion de un antagonista de muerte programada-1, un antagonista de transcripto 4 similar a inmunoglobulina y agentes quimioterapeuticos.
PH12021550834A1 (en) 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament